Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 3, pp 295–300

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

Authors

    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • M. Boyer
    • Sydney Cancer CentreRoyal Prince Alfred Hospital
  • H. C. Chung
    • Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of Medicine
  • S. Y. K. Ong
    • Department of Medical OncologyNational Cancer Centre
  • R. Lim
    • Department of Haematology–OncologyNational University Hospital
  • Benny Zee
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • B. Ma
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • K. C. Lam
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • F. K. F. Mo
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • E. K. W. Ng
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • R. Ho
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
    • Comprehensive Cancer Trials Unit, Department of SurgeryChinese University of Hong Kong, Prince of Wales Hospital
  • S. Clarke
    • Sydney Cancer CentreRoyal Prince Alfred Hospital
  • J. K. Roh
    • Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of Medicine
  • P. Beale
    • Sydney Cancer CentreRoyal Prince Alfred Hospital
  • S. Y. Rha
    • Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of Medicine
  • H. C. Jeung
    • Division of Haematology–Oncology, Yonsei Cancer CenterYonsei University College of Medicine
  • R. Soo
    • Department of Haematology–OncologyNational University Hospital
  • B. C. Goh
    • Department of Haematology–OncologyNational University Hospital
  • A. T. C. Chan
    • Comprehensive Cancer Trials Unit, Department of Clinical OncologyChinese University of Hong Kong, Prince of Wales Hospital
Original Article

DOI: 10.1007/s00280-006-0270-1

Cite this article as:
Yeo, W., Boyer, M., Chung, H.C. et al. Cancer Chemother Pharmacol (2007) 59: 295. doi:10.1007/s00280-006-0270-1

Abstract

Background

The purpose of this study was to evaluate the tolerability and efficacy of irofulven, a DNA interacting acylfulvene analog, as first line therapy for patients with recurrent or metastatic gastric cancer.

Patients and methods

Twenty-three patients with recurrent or metastatic gastric cancer received irofulven at a dose of 0.45 mg/kg administered intravenously over 30-min infusion (up to a maximum of 50 mg), on days 1 and 8, every 3 weeks.

Results

The median number of cycles delivered per patient was 2 (range 1–6). Two patients (9%) had ≥ 1-week delay in administration of subsequent cycle of chemotherapy. For the day 8 chemotherapy, dose reductions were required in seven patients (30%); dose omitting occurred in five patients (22%). Grade 3/4 anemia and neutropenia occurred in 22 and 17% of patients, respectively. There was no grade 4 thrombocytopenia and no neutropenic fever was observed. Of the 20 evaluable patients, there were no responses observed, 3 patients had stable disease after 2 cycles of treatment which was not confirmed by a further assessment. Median overall survival was 6.05 months (95% CI 4.55–9.39).

Conclusions

Irofulven was tolerated at the dose of 0.45 mg/kg on days 1 and 8, every 3 weeks but showed no evidence of antitumor activity in patients with advanced gastric cancer.

Keywords

IrofulvenStomach cancerFirst line chemotherapy

Copyright information

© Springer-Verlag 2006